Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) PT at $10.00

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus recommendation of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.00.

Several equities research analysts have recently weighed in on AQST shares. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. JMP Securities raised their price objective on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a report on Thursday, October 9th. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th. Piper Sandler increased their target price on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th.

Insider Activity at Aquestive Therapeutics

In related news, insider Carl N. Kraus sold 20,272 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total transaction of $141,904.00. Following the sale, the insider owned 282,475 shares of the company’s stock, valued at $1,977,325. This trade represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Cassie Jung sold 67,575 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $7.01, for a total transaction of $473,700.75. Following the transaction, the chief operating officer directly owned 240,771 shares in the company, valued at approximately $1,687,804.71. This represents a 21.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 276,770 shares of company stock worth $1,692,203. 8.35% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after buying an additional 1,333,627 shares during the period. Commonwealth Equity Services LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth about $5,918,000. Pale Fire Capital SE raised its stake in shares of Aquestive Therapeutics by 154.1% during the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock worth $3,873,000 after purchasing an additional 809,928 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $4,381,000. Finally, Aberdeen Group plc bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $3,494,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Down 5.0%

Shares of AQST stock opened at $5.30 on Tuesday. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $7.55. The company has a market capitalization of $646.60 million, a P/E ratio of -7.46 and a beta of 1.79. The business’s 50 day moving average is $5.99 and its two-hundred day moving average is $4.34.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $12.81 million for the quarter, compared to analysts’ expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.